Researchers infused the antioxidant into plastic that is commonly used to coat metal joint replacement implants and tested the antioxidant in a mouse model.
Here are four insights:
1. The COVERNOX-infused particles resulted in a net gain of new bone, whereas the non-infused particles showed no net gain or loss.
2. The researchers tested COVERNOX on smooth bone rather than an articulated joint.
3. However, Edward Schwarz, PhD, director and Richard and Margaret Burton Distinguished Professor of Orthopaedics in the Center for Musculoskeletal Research at URMC, said the results are applicable to human joints.
4. DePuy Synthes plans to conduct more clinical trials for COVERNOX. The trials have yet to receive FDA approval.
More articles on orthopedics:
Dr. Raymond DeLorenzi joins First Choice Medical Group: 3 notes
Orthopedic surgeon leader to know: Dr. Megan Anderson of Boston Children’s Hospital
Orthopedic surgeon to know: Dr. Jeffrey Meisles of Orthopedic Specialists
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.
